Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Review

Hypertriglyceridemia: its etiology, effects and treatment

George Yuan, Khalid Z. Al-Shali and Robert A. Hegele
CMAJ April 10, 2007 176 (8) 1113-1120; DOI: https://doi.org/10.1503/cmaj.060963
George Yuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khalid Z. Al-Shali
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Hegele
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
Submit a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
References
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Minimum 7 characters.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'. Minimum 12 characters.
Your organization, institution's or residential address.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

  • DHA/EPA Omega-3 Fatty Acids are Effective for Triglyceride-lowering
    Bruce J Holub
    Posted on: 27 April 2007
  • Posted on: (27 April 2007)
    DHA/EPA Omega-3 Fatty Acids are Effective for Triglyceride-lowering
    • Bruce J Holub

    Dear Editor:

    I am responding to the informative and well-written article by Drs. Yuan, Al-Shali, and Hegele entitled “Hypertriglyceridemia: its etiology, effects and treatments” as published in CMAJ April 10, 2007: 176 (8): 1103 -1120. I wish to provide evidence-based information herein to correct statements made in this article with respect to the potential use of omega -3 fatty acids from fish oils in the form...

    Show More

    Dear Editor:

    I am responding to the informative and well-written article by Drs. Yuan, Al-Shali, and Hegele entitled “Hypertriglyceridemia: its etiology, effects and treatments” as published in CMAJ April 10, 2007: 176 (8): 1103 -1120. I wish to provide evidence-based information herein to correct statements made in this article with respect to the potential use of omega -3 fatty acids from fish oils in the form of DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) for triglyceride lowering.

    The article states that “Daily consumption of 4g of omega-3 fatty acids, along with restricted energy and saturated-fat intakes, can reduce plasma triglyceride levels by as much as 20%. However, omega-3 fatty acids are rarely effective when used as the sole triglyceride-lowering therapy.” In an earlier review in the CMAJ(1), evidence for more pronounced triglyceride-lowering upon DHA/EPA supplementation was outlined. As given in detail at www.dhaomega3.org, a freely-accessible website on DHA/EPA – health related topics, calculations from the 65 intervention trials as reviewed by Harris (2) indicates expected lowerings of 25-30% for those with baseline fasting triglyceride levels of 1.70-2.82 mmol/L with DHA/EPA (combined) supplemental intakes of 3g/day as the sole triglyceride -lowering therapy. These typically occur within a 4-wk interval in the absence of any significant dietary advice or change. It is also noteworthy that the American Heart Association Scientific Statement (3) states “for individuals with hypertriglyceridemia, 2 to 4g of DHA/EPA per day, provided as capsules under a physician’s care, are recommended.”

    Triglyceride-lowering of 30% or more with 4g/day of EPA/DHA may be accompanied by a small but significant rise in LDL-cholesterol levels (5- 10%)(2). It is noted that the indirect determination of LDL-cholesterol by the Friedwald equation in our health-care system will often yield a small rise in the estimated levels whenever triglyceride levels are lowered. It is reasonable to suggest that EPA/DHA supplementation should be considered as an added strategic option to the authors’ Table 1 while offering efficacy, safety in most patients, compliance and cost-savings to triglyceride management. This is supported by a recent review (4) directed to family physicians in the U.S.

    Finally, a recent review (5) has concluded that combination therapy with statins and EPA/DHA supplementation has been "consistently shown to be effective, safe, and well-tolerated treatment for combined dyslipidemia”.

    References:

    1)Holub BJ. Clinical Nutrition. Omega-3 fatty acids in cardiovascular care. CMAJ 166:608-615, 2002.

    2)Harris WS. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 (suppl): 1645S-1654S, 1997.

    3)Lichtenstein AH et al. Diet and lifestyle recommendations revision 2006: A statement from the American Heart Association Nutrition Committee. Circulation 114(1): 82-96, 2006.

    4)Pejic RN and Lee DT. Hypertriglyceridemia. J Am Board Fam Med 19 (3): 310-316, 2006.

    5)Nambi V and Ballantyne CM. Combination therapy with statins and omega-3 fatty acids. Am J Cardiol 98 (4A): 34i-38i, 2006.

    Conflict of Interest:

    The following companies, Croda Inc., Ocean Nutrition Canada Ltd., and EPAX AS, manufacturers of omega-3 fish oil concentrates containing DHA/EPA, provide support to the DHA/EPA Omega-3 Institute which offers evidence-based health information on DHA/EPA. Dr. Holub is Director of Scientific Affairs for the Institute.

    Show Less
    Competing Interests: None declared.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 176 (8)
CMAJ
Vol. 176, Issue 8
10 Apr 2007
  • Table of Contents
  • Index by author
  • Canadian Adverse Reaction Newsletter (p 1229 - 1236)

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hypertriglyceridemia: its etiology, effects and treatment
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hypertriglyceridemia: its etiology, effects and treatment
George Yuan, Khalid Z. Al-Shali, Robert A. Hegele
CMAJ Apr 2007, 176 (8) 1113-1120; DOI: 10.1503/cmaj.060963

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Hypertriglyceridemia: its etiology, effects and treatment
George Yuan, Khalid Z. Al-Shali, Robert A. Hegele
CMAJ Apr 2007, 176 (8) 1113-1120; DOI: 10.1503/cmaj.060963
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Classification
    • Triglycerides and atherosclerosis
    • Hypertriglyceridemia and pancreatitis
    • Nonpharmacologic treatment
    • Pharmacologic therapy to lower the risk of cardiovascular disease
    • Target triglyceride goals
    • Conclusions
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Acute pancreatitis secondary to hypertriglyceridemia
  • Coronary artery disease risk and lipidomic profiles are similar in familial and population-ascertained hyperlipidemias
  • Mapping the sites of the lipoprotein lipase (LPL)-angiopoietin-like protein 4 (ANGPTL4) interaction provides mechanistic insight into LPL inhibition
  • Low fasting serum insulin and dementia in nondiabetic women followed for 34 years
  • Approach to Hypertriglyceridemia in the Pediatric Population
  • Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
  • Case 2: Diffuse Papulopustular Rash in an 11-week-old Boy
  • Novel CREB3L3 Nonsense Mutation in a Family With Dominant Hypertriglyceridemia
  • A Functional Variant in APOA5/A4/C3/A1 Gene Cluster Contributes to Elevated Triglycerides and Severity of CAD by Interfering With MicroRNA 3201 Binding Efficiency
  • Hepatic Remnant Lipoprotein Clearance by Heparan Sulfate Proteoglycans and Low-Density Lipoprotein Receptors Depend on Dietary Conditions in Mice
  • Fenofibrate-associated nephrotoxicity: A review of current evidence
  • Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia
  • Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin
  • An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia
  • Rapid Reduction of Severely Elevated Serum Triglycerides with Insulin Infusion, Gemfibrozil and Niacin
  • Genetic determinants of plasma triglycerides
  • Intravenous Injection of Apolipoprotein A-V Reconstituted High-Density Lipoprotein Decreases Hypertriglyceridemia in apoav-/- Mice and Requires Glycosylphosphatidylinositol-Anchored High-Density Lipoprotein-Binding Protein 1
  • Hepatic lipase deficiency in a Middle-Eastern-Arabic male
  • Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study
  • Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus
  • Spectrum and Management of Hypertriglyceridemia Among Children in Clinical Practice
  • Investigation and management of hypertriglyceridaemia
  • (-)-Epigallocatechin Gallate Suppresses Azoxymethane-Induced Colonic Premalignant Lesions in Male C57BL/KsJ-db/db Mice
  • Treating hypertriglyceridemia
  • Treating hypertriglyceridemia
  • Treating hypertriglyceridemia
  • Treating hypertriglyceridemia
  • Apolipoprotein A-V Genetic Variation and Plasma Lipoprotein Response to Fibrates
  • Google Scholar

More in this TOC Section

  • The efficacy and safety of sunscreen use for the prevention of skin cancer
  • Prone positioning for patients with hypoxic respiratory failure related to COVID-19
  • Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
Show more Review

Similar Articles

Collections

  • Topics
    • Endocrinology
    • Drugs: cardiovascular system

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire